Menu Search
Equities

Cassava Sciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PX91:STU

Cassava Sciences Inc

Actions
  • Price (EUR)1.72
  • Today's Change0.121 / 7.58%
  • Shares traded0.00
  • 1 Year change-23.31%
  • Beta-0.8097
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

  • Revenue in USD (TTM)0.00
  • Net income in USD-106.03m
  • Incorporated1998
  • Employees30.00
  • Location
    Cassava Sciences Inc6801 N. Capital of Texas HighwayBuilding 1AUSTIN 78731United StatesUSA
  • Phone+1 (512) 501-2444
  • Fax+1 (512) 614-0414
  • Websitehttps://www.cassavasciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.